ACPIF yields 0.08% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 4
Combined, ACPIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ACPIF + JNJ for your $10,000?
Acen Corporation, together with its subsidiaries, engages in the power generation and trading; and oil and mineral exploration, development, and production activities in the Philippines and internationally. It operates and maintains 81 megawatts (MW) and 52MW wind farms in Ilocos Norte; a 54MW wind farm in Guimaras; a 40MW wind farm in Binh Thuan Province, Vietnam; a 252MW wind farm in Quang Binh Province, Vietnam; a 88MW wind farm in Ninh Thuan, Vietnam; a 75 MW wind farm in South Sulawesi, Indonesia; 80MWdc, 18MWdc, and 45MWdc solar power farms in Negros Occidental; a 120MWdc solar power farm in Alaminos, Laguna; a 63MWdc solar power farm in Palauig, Zambales; a 80MWdc solar power plants in Dak Lak and Khanh Hoa, Vietnam; and 140MWdc and 70MWdc solar power farms in Rajasthan and Gujarat, India. The company also owns and operates a 244MW coal thermal project located in Batangas; 108MW diesel plant in Olongapo City; 20MW diesel power plant in La Union; 48MW diesel plant in Bulacan; 24MW diesel power barge plant in Iloilo; 150MW diesel plant in Pililia, Rizal; 32MW geothermal plant in Santo Tomas, Batangas; and 663MW geothermal plant in West Java, Indonesia. It also engages in the leasing and land development activities; trading of electricity in the wholesale electricity spot market; distribution of petroleum products; financing activities; and advisory/consultancy activities. The company was formerly known as AC Energy Corporation and changed its name to Acen Corporation in July 2022. The company was incorporated in 1969 and is based in Makati City, the Philippines. Acen Corporation is a subsidiary of AC Energy and Infrastructure Corporation.
Full ACPIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.